The results showed no significant difference in TMB in samples comparing SETD2 mutants to BRCA1/2, MMR, and POLE/D1 mutant genes in colorectal cancer, glioma, hepatic carcinoma, NSCLC, renal cell carcinoma, and melanoma (Fig. 2B). This evidence concerns the gene POLE and non-small cell lung carcinoma.